There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Have Watchlists? Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO. Market Events The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. NextCure saw a increase in short interest in the month of June. NextCure Inc (NASDAQ:NXTC) released its quarterly earnings results on Thursday, May, 7th. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field11.add(Validate.Presence, {failureMessage:"This field is required"});field11.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. "NextCure's stock is owned by many different retail and institutional investors. After the session, the Healthcare sector daily volume shifted to […] Real time NextCure Inc (NXTC) stock price quote, stock graph, news & analysis. LAIR-2 is a naturally occurring soluble version of LAIR-1, which binds to and blocks the inhibitory activity of LAIR-1 and thus acts as a decoy protein.Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. This suggests a possible upside of 266.6% from the stock's current price. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Trade NXTC stock for free with recommended broker TD Ameritrade. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Get short term trading ideas from the MarketBeat Idea Engine. Taking a look at stock we notice that its last check on previous day was $8.91 with its price kept floating in the range of $8.70 and $9.10 on the day. NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. NextCure Inc's stock had its IPO on May 9, 2019, making it an older stock than only 0.88% of US equities in our set. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The company issued 5,000,000 shares at $14.00-$16.00 per share. NextCure earned a news sentiment score of -1.2 on InfoTrie's scale. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. SG AMERICAS SECURITIES LLC bought a fresh place in NextCure Inc. (NASDAQ:NXTC). View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. 9 analysts have issued twelve-month price objectives for NextCure's stock. High institutional ownership can be a signal of strong market trust in this company.Earnings for NextCure are expected to decrease in the coming year, from ($1.16) to ($2.56) per share.The P/E ratio of NextCure is -9.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of NextCure is -9.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.NextCure has a P/B Ratio of 0.63. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.According to analysts' consensus price target of $32.70, NextCure has a potential upside of 266.6% from its current price of $8.92.NextCure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.NextCure has received 55.00% “outperform” votes from our community.NextCure does not have a long track record of dividend growth.In the past three months, NextCure insiders have not sold or bought any company stock.Only 9.05% of the stock of NextCure is held by insiders.73.44% of the stock of NextCure is held by institutions.